Product Code: 2210
Point of Care Molecular Diagnostics Market is anticipated to register growth through 2032 owing to its ability to detect causative agents in case of any infectious disease emergencies. POC molecular testing plays a vital role in TAT (turnaround time). It offers access to rapid and sensitive infectious disease diagnostic assays crucial for timely infection control, effective treatment, and accurate diagnosis.
The COVID-19 outbreak has underscored the need to detect the disease rapidly and accurately at much higher scales than ever before. Several benefits offered by point-of-care devices such as the possibility of using more portable and cost-effective instrumentation; eliminating sample transport to a clinical laboratory for analysis; alleviating sample processing; using samples that hardly require trained personnel for collection; and measuring different entities (virus, antigen, antibodies) in symptomatic or asymptomatic patients will spur the product adoption in the coming future.
Besides, strategic initiatives by various governmental bodies, such as funds and grants to support the development of novel products, will also positively influence the overall industry growth. For instance, in 2021, Thermo Fisher Scientific unveiled a manufacturing facility in India. The company's MagMAX Dx prefilled viral/pathogen nucleic acid isolation kits and CoviPath RT-PCR testing kits are developed to offer more precise, faster, and easy-to-use Covid testing solutions.
Overall, the point-of-care molecular diagnostics market is segmented in terms of technology, application, end-use, and region.
Based on technology, the polymerase chain reaction (PCR) diagnostic test segment will register notable gains through 2032. Factors such as the budding use in research and development, medical diagnostics, constant technological advancements, increasing prevalence of diseases, and a rising geriatric population base would add to the segmental expansion.
Considering the application, the infectious disease segment accounted for 80% market share in 2022. The increasing prevalence of respiratory syncytial virus and influenza and the easy availability of rapid diagnostic tests, including screening tests for influenza A and B virus infections, will propel segmental demand over the estimated timeframe.
By end-use, the clinics segment accounted for over USD 10 billion revenue share in 2022. The increasing number of clinics, along with cost-effective treatment and portable point-of-care molecular diagnostics systems that help with accurate and timely diagnostics, will spur market growth by 2032 end.
Regionally, the North America point-of-care molecular diagnostics market will register notable gains throughout 2023-2032. The growth can be attributed to the increasing adoption of point-of-care molecular diagnostics and treatment devices equipped with advanced technology. Also, some of the leading regional market players are constantly investing in R&D and increasing their focus on launching novel products, bolstering regional market growth in the future.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Methodology
- 1.2 Market scope & definitions
- 1.3 Base estimates and calculations
- 1.3.1 North America
- 1.3.2 Europe
- 1.3.3 Asia Pacific
- 1.3.4 Latin America
- 1.3.5 MEA
- 1.4 Forecast calculations
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Point of care molecular diagnostics industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Technology trends
- 2.1.3 Application trends
- 2.1.4 End-use trends
- 2.1.5 Regional trends
Chapter 3 Point of Care Molecular Diagnostics Industry Insights
- 3.1 Industry landscape
- 3.2 Pricing analysis 2018 - 2032
- 3.2.1 Pricing analysis, by region
- 3.2.1.1 North America
- 3.2.1.2 Europe
- 3.2.1.3 Asia Pacific
- 3.2.1.4 Latin America
- 3.2.1.5 Middle East & Africa
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Increasing incidence of infectious diseases
- 3.3.1.2 Increasing R&D funding to reduce time required for molecular diagnostic tests
- 3.3.1.3 Growing awareness about pre-disease diagnostics to control occurrence of diseases
- 3.3.1.4 Technological advancements in DNA sequencing and analysis
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Long product development time
- 3.3.2.2 Complex regulatory process
- 3.4 Growth potential analysis
- 3.4.1 By technology
- 3.4.2 By application
- 3.4.3 By end-use
- 3.5 COVID- 19 impact analysis
- 3.6 Technology landscape
- 3.7 Regulatory landscape
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape
- 4.1 Introduction
- 4.1.1 Abbott Laboratories
- 4.1.2 Bio-Rad Laboratories, Inc
- 4.1.3 BioMérieux SA
- 4.2 Competitive dashboard, 2021
- 4.3 Company matrix analysis, 2021
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic outlook matrix
Chapter 5 Point of Care Molecular Diagnostics Market, By Technology
- 5.1 Key technology trends
- 5.2 Polymerase Chain Reaction (PCR)
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3 In situ hybridization
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.4 Sequecing
- 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.5 Isothermal amplification
- 5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.6 Others
- 5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Point of Care Molecular Diagnostics Market, By Application
- 6.1 Key application trends
- 6.2 Infectious diseases
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.2 Flu
- 6.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.3 Respiratory syncytial virus (RSV)
- 6.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.4 Tuberculosis (TB)
- 6.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.5 HIV
- 6.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.6 Gonorrhea
- 6.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.7 Chlamydia
- 6.2.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.8 Hepatitis C
- 6.2.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.9 Hepatitis B
- 6.2.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.10 COVID-19
- 6.2.10.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.2.11 Others
- 6.2.11.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.3 Oncology
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.4 Hematology
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.5 Others
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Point of Care Molecular Diagnostics Market, By End-use
- 7.1 Key end-use trends
- 7.2 Hospitals
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 7.3 Clinics
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 7.4 Diagnostic centers
- 7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 7.5 Others
- 7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Point of Care Molecular Diagnostics Market, By Region
- 8.1 Key regional trends
- 8.2 North America
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Russia
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 Malaysia
- 8.4.6 Thailand
- 8.4.7 Vietnam
- 8.4.8 Philippines
- 8.4.9 Australia
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Nigeria
- 8.6.3 Egypt
- 8.6.4 Morocco
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 BioMérieux SA
- 9.3 Bio-Rad Laboratories, Inc
- 9.4 Danaher Corporation
- 9.5 Sysmex Corporation
- 9.6 Abaxis Inc
- 9.7 Mesa Biotech (Thermo Fisher Scientific)
- 9.8 Roche Diagnostics
- 9.9 OraSure Technologies, Inc
- 9.10 VIRCELL S.L